Core Insights - Changchun High-tech reported a revenue of 9.807 billion yuan for the first three quarters of 2025, a year-on-year decrease of 5.60% [1] - The net profit attributable to shareholders was 1.165 billion yuan, down 58.23% year-on-year [1] - The company’s subsidiary, Jinsai Pharmaceutical, achieved a revenue of 8.213 billion yuan, a slight increase of 0.61%, but its net profit dropped by 49.96% to 1.421 billion yuan [1] Financial Performance - Changchun High-tech's subsidiaries showed varied performance: - Jinsai Pharmaceutical: Revenue of 8.213 billion yuan, net profit of 1.421 billion yuan [1] - Baike Biotechnology: Revenue of 0.474 billion yuan, net loss of 0.158 billion yuan [1] - Huakang Pharmaceutical: Revenue of 0.542 billion yuan, net profit of 0.036 billion yuan [1] - Gaoxin Real Estate: Revenue of 0.544 billion yuan, net profit of 0.0002327 billion yuan [1] - R&D expenses for the period amounted to 1.733 billion yuan, an increase from 1.41 billion yuan in the previous period [4] Strategic Developments - Changchun High-tech announced a collaboration between Jinsai Pharmaceutical and Denmark's ALK to develop and commercialize specific immunotherapy products in China [1][2] - The partnership aims to enhance Jinsai's pediatric business and strengthen its competitive advantage in the pediatric field [2] - The company has received multiple approvals for clinical trial applications for its products, indicating ongoing innovation and regulatory progress [2][3] Innovation and R&D Focus - The company has been actively adjusting its strategy and increasing investment in innovation, establishing core technology platforms with independent intellectual property rights [3] - It aims to cover the entire process of innovative drug design, screening, evaluation, process development, and formulation research, integrating artificial intelligence to enhance R&D efficiency [3] - The focus is on high-demand therapeutic areas, particularly in endocrine metabolism and pediatric fields, to support sustainable development and internationalization goals [3]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received approval from the National Medical Products Administration for a clinical trial of GenSci139 in patients with advanced solid tumors, which may enhance the company's business scope and core competitiveness [1]. Group 1 - Jinsai Pharmaceutical has been granted a clinical trial approval for GenSci139, a dual-specific antibody-drug conjugate targeting EGFR and HER2 [1]. - GenSci139 is developed independently by Jinsai Pharmaceutical and possesses its own intellectual property rights [1]. - Successful progress in the clinical trial application could help the company expand its business range and optimize its product structure [1].

证券日报网讯 10月20日晚间，长春高新发布公告称，近日，公司子公司——长春金赛药业有限责任公 司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用GenSci139单药在晚 期实体瘤患者中开展临床试验。 （编辑 姚尧） ...

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for GenSci139 in patients with advanced solid tumors, which may enhance the company's business scope and product structure [1] Group 1 - The approval allows for the clinical trial of GenSci139, a drug intended for advanced solid tumor patients [1] - Successful progress in the clinical trial application is expected to broaden the company's business range and optimize its product structure [1] - The initiative aims to enrich and improve the strategic product line layout, thereby enhancing the company's core competitiveness [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for clinical trials of GenSci139 in patients with advanced solid tumors [1] Group 1: Product Development - GenSci139 is a dual-specific antibody-drug conjugate (BsADC) independently developed by Jinsai Pharmaceutical, targeting EGFR and HER2 [1] - The product utilizes a proprietary, highly stable, and hydrophilic cleavable linker, covalently connected to a potent topoisomerase I inhibitor as an effective payload [1] - GenSci139 specifically recognizes and binds to tumor cells expressing EGFR and/or HER2, blocking the signaling pathways of EGFR homodimers, HER2 homodimers, and EGFR-HER2 heterodimers, thereby inhibiting tumor cell growth [1] Group 2: Mechanism of Action - The drug can internalize upon binding to tumor cells expressing EGFR and/or HER2, releasing the effective payload to kill tumor cells [1]

长春高新（000661）(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称"金赛药业")收 到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用GenSci139单药在晚期实 体瘤患者中开展临床试验。 ...

智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称"金赛药 业")收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用GenSci139单药在 晚期实体瘤患者中开展临床试验。 ...

人民财讯10月20日电，长春高新（000661）10月20日公告，公司子公司长春金赛药业有限责任公司近日 收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用GenSci139单药在晚期 实体瘤患者中开展临床试验。 ...